9 Meters Biopharma (9 Meters Biopharma) ROC % : -351.59% (As of Mar. 2023)

View and export this data going back to 2016. Start your Free Trial

What is 9 Meters Biopharma ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. 9 Meters Biopharma's annualized return on capital (ROC %) for the quarter that ended in Mar. 2023 was -351.59%.

As of today (2024-05-31), 9 Meters Biopharma's WACC % is 0.00%. 9 Meters Biopharma's ROC % is 0.00% (calculated using TTM income statement data). 9 Meters Biopharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.

9 Meters Biopharma ROC % Historical Data

The historical data trend for 9 Meters Biopharma's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

9 Meters Biopharma ROC % Chart

9 Meters Biopharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROC %

Get a 7-Day Free Trial

-227.96

-367.23

-514.89

-1,925.08

-354.62

9 Meters Biopharma Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
ROC %	Get a 7-Day Free Trial															-2,792.14	-2,966.55	-220.47	-165.86	-351.59

9 Meters Biopharma ROC % Calculation

9 Meters Biopharma's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2022 is calculated as:

	ROC % (A: Dec. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2021 )	+	Invested Capital (A: Dec. 2022 ))	/ count )
=	-42.017 * ( 1 - 0% )	/	( (1.877	+	21.82)	/ 2 )
=	-42.017	/	11.8485
=	-354.62 %

where

	Invested Capital		(A: Dec. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	50.174	-	6.769	-	( 46.993	-	max(0, 8.457	-	49.985	+	46.993	))
=	1.877

	Invested Capital		(A: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	33.148	-	9.006	-	( 12.646	-	max(0, 30.696	-	33.018	+	12.646	))
=	21.82

9 Meters Biopharma's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2023 is calculated as:

	ROC % (Q: Mar. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2022 )	+	Invested Capital (Q: Mar. 2023 ))	/ count )
=	-51.148 * ( 1 - 0% )	/	( (21.82	+	7.275)	/ 2 )
=	-51.148	/	14.5475
=	-351.59 %

where

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	33.148	-	9.006	-	( 12.646	-	max(0, 30.696	-	33.018	+	12.646	))
=	21.82

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9.313	-	8.418	-	( 6.939	-	max(0, 15.577	-	9.197	+	6.939	))
=	7.275

Note: The Operating Income data used here is four times the quarterly (Mar. 2023) data.

9 Meters Biopharma (OTCPK:NMTRQ) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, 9 Meters Biopharma's WACC % is 0.00%. 9 Meters Biopharma's ROC % is 0.00% (calculated using TTM income statement data). 9 Meters Biopharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

9 Meters Biopharma ROC % Related Terms

Thank you for viewing the detailed overview of 9 Meters Biopharma's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.

9 Meters Biopharma (9 Meters Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 9 Meters Biopharma Inc (OTCPK:NMTRQ) » Definitions » ROC %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4509 Creedmoor Road, Suite 201, Raleigh, NC, USA, 27612

Website

https://www.9meters.com

9 Meters Biopharma Inc is a clinical-stage biopharmaceutical company focused on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. Its products include NM-002, Larazotide, NM-003, and others.

Executives

Bethany Sensenig	officer: Chief Financial Officer	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
John Temperato	director, officer: Chief Executive Officer	C/O MELINTA THERAPEUTICS,INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Mark A Sirgo	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Michael T. Constantino	director	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Samantha Ventimiglia	director	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Edward J Sitar	officer: Chief Financial Officer	39 FLAMING ARROW ROAD, MAHWAH NJ 07430
Orbimed Israel Biofund Gp Limited Partnership	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
Yehuda Michael Rice	director	155 WALNUT STREET, ENGLEWOOD NJ 07631
Nissim Darvish	director, 10 percent owner	C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Orbimed Israel Gp Ltd.	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Sandeep Laumas	director, officer: Executive Chairman	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Jay P. Madan	director, officer: President	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Roy Proujansky	director	144 PAU NEL DRIVE, LANDENBERG PA 19350
Christopher P. Prior	director, officer: Chief Executive Officer	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
June Sherie Almenoff	officer: COO and Chief Medical Officer	C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019